In ₹ Crore except Per Share Latest Annual | IPCALAB FY26 | TORNTPHARM FY26 | ALKEM FY26 | JBCHEPHARM FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 43.84× | 77.05× | ◆ 26.55× | — | 51.80× -15% | |
| P/B | 5.25× | 9.48× | ◆ 4.26× | — | 6.87× -24% | |
| EV/EBITDA | 25.10× | 39.37× | ◆ 20.54× | — | 29.96× -16% | |
| Market Cap | ₹50,032 Cr | ₹1.67L Cr | ₹61,102 Cr | — | ₹1.14L Cr -56% | |
| Growth | ||||||
| Revenue CAGR 3Y | ◆ 15.60% | 13.27% | 8.25% | 9.61% | 9.61% +62% | |
| Revenue CAGR 5Y | 12.22% | 11.80% | 10.09% | ◆ 15.22% | 11.80% +4% | |
| Net Income CAGR 3Y | ◆ 35.20% | 19.75% | 32.67% | 20.06% | 20.06% +75% | |
| Revenue YoY (latest Q) | 20.76% | ◆ 54.85% | 10.95% | -4.77% | 10.95% +90% | |
| Net Income YoY (latest Q) | ◆ 82.18% | 3.28% | -22.00% | -30.42% | -22.00% +474% | |
| Profitability | ||||||
| EBITDA Margin | 20.51% | ◆ 32.61% | 20.43% | 26.70% | 26.70% -23% | |
| Net Income Margin | 12.27% | 15.29% | 15.98% | ◆ 17.10% | 15.98% -23% | |
| Return on Common Equity | 11.98% | 12.30% | 16.04% | ◆ 17.06% | 16.04% -25% | |
| Return on Capital Employed | 15.51% | 9.56% | 16.30% | ◆ 21.13% | 16.30% -5% | |
| Return on Assets | 9.57% | 4.82% | 11.26% | ◆ 14.28% | 11.26% -15% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.07× | 0.84× | 0.11× | ◆ 0.00× | 0.11× -36% | |
| Interest Coverage | 20.55× | 8.94× | 16.32× | ◆ 166.06× | 16.32× +26% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹9,646 Cr | ₹13,980 Cr | ₹14,712 Cr | ₹4,148 Cr | ₹13,980 Cr -31% | |
| Net Income | ₹1,184 Cr | ₹2,138 Cr | ₹2,351 Cr | ₹709 Cr | ₹2,138 Cr -45% | |
| Total Assets | ₹12,370 Cr | ₹44,312 Cr | ₹20,873 Cr | ₹4,969 Cr | ₹20,873 Cr -41% | |
| EPS | ₹44.98 | ₹63.92 | ₹192.51 | ₹45.16 | ₹63.92 -30% | |
| Book Value per Share | ₹375.41 | ₹519.56 | ₹1,200.25 | ₹258.98 | ₹519.56 -28% | |